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The major rat kidney in vitro degradation products of the rat atria1 natriuretic factor analog, H-Cys7- 
Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr28-NH, (with a 
Cysz7-Cysz3 disulfide bridge), have been identified. The degradation products are the C-terminal modified 
compounds rANF7-27, rANF7_26r and rANFTmZ5. 
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1. INTRODUCTION 
The discovery of a potent family of vasodilato- 
ry, natriuretic and diuretic peptides (collectively 
referred to as atria1 natriuretic factors) has led to 
considerable research activity (reviews [l-4]). 
However, from a therapeutic standpoint, one of 
the main drawbacks of ANF is the relatively short 
duration of its biological action (~30 min). The 
short duration of action is most likely attributable 
to metabolism of the active peptide. Therefore, an 
attractive approach to overcome the stability prob- 
lem is to design analogs that resist proteolysis but 
maintain full biological activity. This report details 
our initial attempts to identify the ‘weak links’ 
(proteolytic sites) present in the rANF analog 
rANF7_2s-NH2, a shortened carboxypeptidase 
stabilized analog (residues l-6 are deleted from the 
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endogenous form) that shows full biological activi- 
ty. We have examined kidney preparations because 
this tissue is both a potent source of proteolytic ac- 
tivity [5,6] and a target of ANF action [7]. 
2. MATERIALS AND METHODS 
2.1. Peptide 
rANF7-2s-NH2 was prepared by the solid-phase 
method [8] (details to be reported elsewhere). 
2.2. Enzymatic degradation 
For the degradation studies, rat kidneys were ex- 
cised, minced ahd homogenized in ice cold 50 mM 
sodium phosphate-buffered saline (10 ml/kidney) 
at pH 7.4. The homogenate was centrifuged for 20 
min at 48 000 x g at 4°C. The supernatant (100 ~1) 
was added to 10 nmol rANF7_28-NH2 (freeze-dried 
powder), and incubated at 37°C for various times. 
Enzymatic activity was destroyed by dipping the 
sample tubes into boiling water for 2 min. The 
tubes were centrifuged at 4000 rpm for 2 min. The 
supernatants (50 ~1) were then subjected to reverse 
phase HPLC [column: Vydac 218TP54 (25 cm x 
4.6 mm ID), with a Macrosphere 300 A C-4, 7 pm, 
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guard column (1 cm x 4.6 mm ID)]. Mobile 
phase: A = HzO/CH&N (85/15) containing 
0.01 M ammonium acetate and B = H20/CH&N 
(SO/SO) containing 0.01 M ammonium acetate. A 
linear gradient was run from 0% B to 60% B over 
30 min at a flow rate of 1.5 ml/min. For structure 
identification fractions from four separate 10 min 
incubations were pooled, freeze dried and ana- 
lyzed . 
2.3. Amino acid sequence analysis 
Automated Edman degradations were per- 
formed on a model 470A protein-peptide se- 
quencer (Applied Biosystems) with reagents, 
instructions, and standard programs supplied by 
the manufacturer. The phenylthiohydantoin 
(PTH)-derivatized amino acids were analyzed at 
Time 0 min. rANF,_2S-NH2 
T 
0.05 AU 
A214nm 
I 0.05 AU 
Fig. 1. HPLC chromatogram of rANF7_28-NHZ after in- 
cubation with kidney homogenates. 
Table 1 
Peak Peptide [M + H] + talc” [M + H] + obsb 
1 rANF,-2s 1908 1908 
2 rANF7-26 2055 2055 
3 rANF7-27 2211 2211 
a The calculated and observed [M + H] are reported us- 
ing nominal masses 
b VG analytical ZAB high field mass spectrometer 
operating at V,,, = 8 kV for 3000 mass range at full 
sensitivity 
each cycle on a model 120 PTH analyzer (Applied 
Biosystems) directly on-line with the sequencer. 
3. RESULTS AND DISCUSSION 
The degradation of rANF7-2s-NH2 by rat kidney 
homogenates proceeds quite rapidly (tr,z -3.5 
min). The HPLC elution profile of rANF7-28-NHZ 
after incubation with rat kidney homogenates 
shows several distinct metabolites (fig. 1). These 
compounds, identified by amino acid analysis, se- 
quencing and FAB-MS (table 1), are rANF7_27, 
rANF,-26, and rANF,-25. These products most 
likely result from a trypsin-like cleavage at Arg2’ 
(liberating Tyr-NH2) and subsequent carboxypep- 
tidase action. The involvement of a specific 
metallo dipeptidyl dipeptidase [9, lo] for cleaving 
rANF7-2’ to rANF,-2s appears plausible in this rat 
kidney preparation (note relatively reduced quanti- 
ty of rANF7_&. Previous structure-activity studies 
have demonstrated an order of magnitude loss in 
potency with the successive removal of Arg2’ and 
PheZh [ll]. We conclude that the critical proteo- 
lysis of rANF7-2s-NHz that results in a relatively 
inactive rANF fragment occurs at the Phe26-Arg27 
linkage. We are currently examining the degrada- 
tion profiles of rANF7_zs-NH2 with various tissue 
preparations and peptidase inhibitors. 
ADDENDUM 
While our manuscript was in preparation reports 
describing ANF degradation by kidney brush 
border membrane enzymes were published [ 12,131. 
Our results are qualitatively different and reflect 
degradation by soluble proteases present in rat 
kidney extracts. 
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